ArticleNeuropsychiatric disease and treatment2009
Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature.
Article in Neuropsychiatric disease and treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial.Clinical drug investigation · 2011Trial
- Article
- Abnormal Behavior Episodes Associated With Zonisamide in Three Dogs: A Case Report.Frontiers in veterinary science · 2021Article
- Safety and Efficacy of Zonisamide in Patients with Epilepsy: A Post-Marketing Surveillance Study.Journal of epilepsy research · 2015Article
- Zonisamide in the management of epilepsy in the elderly.Clinical interventions in aging · 2015Review
- Zonisamide decreases current-source density of high Beta frequency of electroencephalogram.Journal of epilepsy research · 2013Article
- New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?Therapeutic advances in drug safety · 2011Review
- Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study.Neurology · 2010Article
- 2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zonisamide (ZNS) efficacy and safety in epilepsy have been demonstrated in four double-blind, placebo-controlled studies. In the present article, we examined all long-term studies performed with this drug. Nine open-label studies, in which ZNS had been administered as an add-on or as monotherapy to epileptic patients for at least 6 months, were selected for our analysis. Four outcome measures were searched. Retention of this drug after 1 year varied between 45% and 65%. The percentages of patients achieving a >/=50% seizure reduction, with respect to baseline, ranged between 37% and 65%. In patients with drug-resistant forms of epilepsy, the percentage of patients reaching a 6-month seizure freedom period was 9%. The percentages of patients who discontinued the experimental drug due to adverse effects ranged between 4% and 24%. Somnolence and dizziness were the most frequently reported adverse effects. Long-term studies demonstrate that ZNS has a good efficacy and tolerability profile, and support its use as adjunctive therapy for epileptic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.